drugset

drugset / Trial / NCT06310590

Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma

NCT06310590 ↗

Phase 1 Completed 40 enrolled Chengdu New Radiomedicine Technology Co. LTD.

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to evaluate the safety and efficacy of NRT6003 Injection in patients with unresectable HCC.

Timeline

Start: 2023-08-08
Primary completion: 2025-06-10
Completion: 2025-06-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NRT6003	Other / unclassified	—	—

Indications